Ziprasidone in the management of schizophrenia : the QT interval issue in context.
about
Aggression in autism spectrum disorder: presentation and treatment optionsVentricular dysrhythmias associated with poisoning and drug overdose: a 10-year review of statewide poison control center data from California.Assessing QT interval prolongation and its associated risks with antipsychotics.An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.Maintenance therapies in bipolar disorders.Ziprasidone hydrocloride: what role in the management of schizophrenia?The improvement of the dissolution rate of ziprasidone free base from solid oral formulationsIloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum DisorderDrug safety evaluation of ziprasidone.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?Values of using QTc and N-terminal fragment of B-type natriuretic peptide as markers for early detection of acute antipsychotic drugs-induced cardiotoxicity.Ziprasidone and QTc Prolongation.Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.Probable association between ziprasidone and worsening hypertension.Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats.Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.
P2860
Q26744346-E8D7B75E-DEDB-440C-8107-378A0C1E5255Q30883223-B71976E1-D9AF-4A89-A70B-63FCF345A799Q33160123-9270A45B-0F94-4D4E-B6ED-3D536DCC928FQ33715077-D9778223-9C11-4D2A-98B6-111E0607A27AQ34268760-649FF292-EFEA-4F5E-A90D-194DE15831B0Q34357931-6A7657B7-3951-4E11-8A93-F420DD2F278AQ35868320-14D01B74-B833-4CC7-8EA1-8D7803F2F766Q37038991-8147EAD8-21BC-43C7-800B-FD5DF1E399C6Q37595760-58809F11-71DF-4680-98CF-DDD582558416Q37844574-013D9F43-FCC7-440E-856C-D0A4D66133F0Q37896627-52282581-606E-47C8-9691-3C0F263293F4Q39130883-ACA561AE-B380-4E5C-A40E-A8F896AC9E12Q40899184-59A7F770-0E24-4E27-B9DD-5D4DDDC2AB24Q43184656-EC8074B3-9874-4676-B9AD-52272FC16C73Q43258119-C1714C79-91AF-4617-BB96-5FE355D64214Q46477497-F23532C0-F046-457D-AAEE-F853E73A3848Q46487525-99D5194A-9687-4348-900F-ADFBF88A447EQ46533468-09CFB79B-387C-4139-BA29-590F7DAF881DQ48013318-DB5BD5BD-3424-4E73-A568-D54B0130C2F1Q50930340-CB90A5EB-9C5C-481C-BF39-FCC42BA91CA4Q51372030-5414C75D-D8E7-4C9F-91E9-B8C6BE80B536Q51507196-09F52457-37CF-45F0-BF29-FA381A9E66AA
P2860
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@ast
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@en
type
label
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@ast
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@en
prefLabel
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@ast
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@en
P1433
P1476
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
@en
P2093
David Taylor
P304
P356
10.2165/00023210-200317060-00004
P577
2003-01-01T00:00:00Z
P5875
P6179
1013429957